PL1633391T3 - Stabilizowane farmaceutycznie kompozycje peptydowe - Google Patents
Stabilizowane farmaceutycznie kompozycje peptydoweInfo
- Publication number
- PL1633391T3 PL1633391T3 PL04735873T PL04735873T PL1633391T3 PL 1633391 T3 PL1633391 T3 PL 1633391T3 PL 04735873 T PL04735873 T PL 04735873T PL 04735873 T PL04735873 T PL 04735873T PL 1633391 T3 PL1633391 T3 PL 1633391T3
- Authority
- PL
- Poland
- Prior art keywords
- peptide compositions
- stabilized pharmaceutical
- pharmaceutical peptide
- stabilized
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300820 | 2003-06-03 | ||
US47628203P | 2003-06-05 | 2003-06-05 | |
DKPA200400063 | 2004-01-19 | ||
US53848704P | 2004-01-22 | 2004-01-22 | |
PCT/DK2004/000381 WO2004105790A1 (en) | 2003-06-03 | 2004-06-03 | Stabilized pharmaceutical peptide compositions |
EP04735873A EP1633391B1 (en) | 2003-06-03 | 2004-06-03 | Stabilized pharmaceutical peptide compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1633391T3 true PL1633391T3 (pl) | 2012-03-30 |
Family
ID=33494168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04735873T PL1633391T3 (pl) | 2003-06-03 | 2004-06-03 | Stabilizowane farmaceutycznie kompozycje peptydowe |
Country Status (5)
Country | Link |
---|---|
US (1) | US8114959B2 (pl) |
EP (1) | EP1633391B1 (pl) |
JP (1) | JP2007524592A (pl) |
PL (1) | PL1633391T3 (pl) |
WO (1) | WO2004105790A1 (pl) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006024631A2 (en) * | 2004-08-31 | 2006-03-09 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
EP1959986B1 (en) | 2005-11-07 | 2014-07-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
ES2779992T3 (es) | 2005-12-20 | 2020-08-21 | Univ Duke | Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
JP5864834B2 (ja) | 2006-09-22 | 2016-02-17 | ノボ・ノルデイスク・エー/エス | プロテアーゼ耐性のインスリンアナログ |
SG177953A1 (en) * | 2007-01-05 | 2012-02-28 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
US20100190706A1 (en) * | 2007-06-01 | 2010-07-29 | Novo Nordisk A/S | Stable Non-Aqueous Pharmaceutical Compositions |
WO2008145728A1 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
CA2690164A1 (en) * | 2007-06-16 | 2008-12-24 | Enigma Diagnostics Limited | Compositions |
ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー/エス | プロテアーゼ安定化インスリンアナログ |
PT2254906T (pt) | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
CN102088989B (zh) | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
JP6108659B2 (ja) | 2008-06-17 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト |
AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
MX366935B (es) | 2009-08-14 | 2019-07-31 | Phasebio Pharmaceuticals Inc | Peptidos intestinales vasoactivos modificados. |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CA2788304A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
EP2552478B1 (en) | 2010-03-31 | 2016-12-21 | Stabilitech Ltd. | Excipients for stabilising viral particles |
WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
WO2012012460A1 (en) * | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
EP2526971A1 (en) | 2011-05-25 | 2012-11-28 | ArisGen SA | Mucosal delivery of drugs |
ES2669190T3 (es) | 2011-06-06 | 2018-05-24 | Phasebio Pharmaceuticals, Inc. | Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión |
JP6184404B2 (ja) | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン/glp−1レセプターコアゴニスト |
EP2723367B1 (en) | 2011-06-22 | 2017-05-03 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP6396211B2 (ja) | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
GB201117233D0 (en) * | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
CA2870313A1 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
WO2014041375A1 (en) | 2012-09-17 | 2014-03-20 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN104870009B (zh) | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
WO2014147129A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
SG11201506804VA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of hydantoin containing peptide products |
AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
CA2947982C (en) | 2014-05-08 | 2022-11-29 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
WO2016059593A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of protein drugs and process for its preparation |
WO2016069409A1 (en) | 2014-10-27 | 2016-05-06 | Latitude Pharmaceuticals, Inc. | Parenteral glucagon formulations |
WO2016130518A2 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN110087674B (zh) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | 含胰岛素的药物组合物 |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
WO2020127476A1 (en) | 2018-12-19 | 2020-06-25 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
WO2021123228A1 (en) | 2019-12-18 | 2021-06-24 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising glp-1 analogue |
EP4154869A1 (en) * | 2020-05-22 | 2023-03-29 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glp-2 |
EP4281039A2 (en) | 2021-01-25 | 2023-11-29 | Mylan Ireland Limited | Pharmaceutical glp peptide compositions and methods of preparation thereof |
CN116159027A (zh) * | 2022-12-29 | 2023-05-26 | 江苏诺泰澳赛诺生物制药股份有限公司 | 一种司美格鲁肽冻干药物组合物及其制备方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468346A (en) * | 1983-10-27 | 1984-08-28 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to porcine immunoglobulins |
WO1988008673A1 (en) * | 1987-05-14 | 1988-11-17 | Commonwealth Scientific And Industrial Research Or | Whey protein fractions |
WO1990000200A1 (en) | 1988-06-27 | 1990-01-11 | Genex Corporation | Thermal release of recombinant protein into culture media |
DE69013471T2 (de) | 1989-12-05 | 1995-03-30 | Merck & Co Inc | Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe. |
DE4002066A1 (de) | 1990-01-25 | 1991-08-01 | Basf Ag | Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
SE9101381D0 (sv) | 1991-05-07 | 1991-05-07 | Tomas Moks | Peptide hormone solution |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
JP3631490B2 (ja) | 1992-05-13 | 2005-03-23 | ノバルティス ファーマ株式会社 | シクロスポリン含有眼科用組成物 |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
CA2176462A1 (en) | 1993-11-19 | 1995-05-26 | Larry P. Feigen | Transdermal composition of n-[n-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-l-.alpha.-aspartyl]-l-phenylalanine or its esters and their pharmaceutically acceptable salts |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
WO1995022560A1 (en) | 1994-02-22 | 1995-08-24 | The Syntex-Synergen Neuroscience Joint Venture | Pharmaceutical formulations of cntf |
US5652216A (en) * | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
CA2157219C (en) | 1994-08-31 | 2010-10-05 | Munehiro Noda | Process for purifying recombinant human serum albumin |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
ATE234625T1 (de) | 1994-12-23 | 2003-04-15 | Novo Nordisk As | Glp-1 zusammensetzungen mit verlängerter wirkdauer |
DE69620877T2 (de) | 1995-02-06 | 2002-12-12 | Genetics Inst | Arzneimittelformulierungen für il-12 |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
AU5996996A (en) | 1995-06-02 | 1996-12-18 | Novo Nordisk A/S | Al/fe-treatment of a protein solution, followed by membrane concentration |
US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
JPH10101696A (ja) | 1996-08-08 | 1998-04-21 | Shinotesuto:Kk | 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質 |
US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
CA2278199A1 (en) * | 1997-01-20 | 1998-07-23 | Japan Energy Corporation | Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method |
CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
AU4894697A (en) | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
ATE237636T1 (de) | 1997-10-24 | 2003-05-15 | Genentech Inc | Reinigung von molekülen |
AU1617399A (en) | 1997-12-05 | 1999-06-28 | Eli Lilly And Company | Glp-1 formulations |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
WO1999043341A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
EP1060191B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
ATE269103T1 (de) * | 1998-03-13 | 2004-07-15 | Novo Nordisk As | Stabilisierte wässerige glukagonlösungen enthaltend detergenzien |
AU3772199A (en) * | 1998-05-01 | 1999-11-23 | University Of Tennessee Research Corporation, The | Flow cytometric characterization of amyloid fibrils |
AU765584B2 (en) * | 1998-09-17 | 2003-09-25 | Eli Lilly And Company | Protein formulations |
WO2000037098A1 (en) * | 1998-12-22 | 2000-06-29 | Eli Lilly And Company | Shelf-stable formulation of glucagon-like peptide-1 |
EP1609478A1 (en) | 1999-01-14 | 2005-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptide formulations |
US6444788B1 (en) * | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
BR0009040A (pt) | 1999-03-17 | 2001-12-18 | Novo Nordisk As | Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto |
EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
PT1242121E (pt) | 1999-12-16 | 2005-05-31 | Lilly Co Eli | Composicoes polipeptidicas com estabilidade melhorada |
US7022674B2 (en) * | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
US6734162B2 (en) | 2000-01-24 | 2004-05-11 | Minimed Inc. | Mixed buffer system for stabilizing polypeptide formulations |
HUP0204281A3 (en) * | 2000-01-27 | 2007-03-28 | Lilly Co Eli | Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds |
EP1396499A3 (en) | 2000-01-27 | 2004-12-29 | Eli Lilly And Company | Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds |
US6844321B2 (en) * | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
AU2001248277A1 (en) | 2000-04-06 | 2001-10-23 | Novo-Nordisk A/S | Shock heat treatment of polypeptides |
ATE424413T1 (de) * | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
WO2002048192A2 (en) * | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
CN1501809B (zh) | 2000-12-13 | 2012-10-10 | 伊莱利利公司 | 应用胰高血糖素样促胰岛肽的长期治疗方案 |
US20020151467A1 (en) * | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
GB2371227A (en) | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
AU2002233089B2 (en) * | 2001-02-16 | 2005-12-22 | Conjuchem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders |
US6573237B2 (en) * | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
EP1391209A4 (en) | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
ES2298378T3 (es) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
CN1335182A (zh) | 2001-08-08 | 2002-02-13 | 华中科技大学 | 胰岛素口腔喷剂及其制备工艺 |
CA2452044A1 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
JP2005508360A (ja) | 2001-10-19 | 2005-03-31 | イーライ・リリー・アンド・カンパニー | Glp−1およびインスリンの二相混合物 |
DK1344533T3 (da) | 2002-03-15 | 2007-01-08 | Natimmune As | Farmaceutiske præparater, der omfatter mannosebindende lectin |
JP2005535569A (ja) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー/エス | Glp−1アゴニスト及び心臓血管合併症 |
DE60321473D1 (de) | 2002-09-25 | 2008-07-17 | Novo Nordisk As | Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet |
WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
ES2380437T3 (es) * | 2003-06-03 | 2012-05-11 | Novo Nordisk A/S | Composiciones farmacéuticas de péptido GLP-1 estabilizadas |
CA2527743A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US20060287221A1 (en) * | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
JP4800959B2 (ja) | 2003-11-13 | 2011-10-26 | ノヴォ ノルディスク アー/エス | 糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物 |
-
2004
- 2004-06-03 JP JP2006508133A patent/JP2007524592A/ja not_active Withdrawn
- 2004-06-03 EP EP04735873A patent/EP1633391B1/en not_active Expired - Lifetime
- 2004-06-03 PL PL04735873T patent/PL1633391T3/pl unknown
- 2004-06-03 WO PCT/DK2004/000381 patent/WO2004105790A1/en active Application Filing
-
2008
- 2008-08-01 US US12/184,531 patent/US8114959B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US8114959B2 (en) | 2012-02-14 |
EP1633391B1 (en) | 2011-10-19 |
US20080318865A1 (en) | 2008-12-25 |
EP1633391A1 (en) | 2006-03-15 |
JP2007524592A (ja) | 2007-08-30 |
WO2004105790A1 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1633391T3 (pl) | Stabilizowane farmaceutycznie kompozycje peptydowe | |
PL1633390T3 (pl) | Stabilizowane kompozycje farmaceutyczne peptydu glp-1 | |
GB2389530B (en) | Pharmaceutical compositions | |
GB0320382D0 (en) | Pharmaceutical compositions | |
GB0327723D0 (en) | Pharmaceutical compositions | |
AU2003302603A8 (en) | Improved opioid pharmaceutical compositions | |
AU2003291103A8 (en) | Pharmaceutical composition | |
ZA200605080B (en) | Pharmaceutical compositions | |
GB2391473B (en) | Pharmaceutical compositions | |
HU0301154D0 (en) | Pharmaceutical composition | |
GB0300531D0 (en) | Pharmaceutical compositions | |
GB0300427D0 (en) | Pharmaceutical composition | |
AU2003250372A8 (en) | Pharmaceutical composition | |
HK1084670A1 (en) | Pharmaceutical compositions comprising cabbinochreme type compounds | |
EP1648411A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0307866D0 (en) | Pharmaceutical composition | |
EP1699458A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0329232D0 (en) | Pharmaceutical composition | |
GB0317663D0 (en) | Pharmaceutical composition | |
HU0302441D0 (en) | Pharmaceutical compositions having antibiothic effect | |
GB0213481D0 (en) | Pharmaceutical compositions | |
GB0300885D0 (en) | Pharmaceutical composition | |
EP1480649A4 (en) | STABLE PHARMACEUTICAL COMPOSITIONS | |
GB0306933D0 (en) | Pharmaceutical composition | |
GB0305579D0 (en) | Pharmaceutical compositions |